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Joo-Ho Chung, M.D.
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Departments of Dermatology and 
1Pharmacology, Kyung Hee University College of Medicine, Seoul, Korea
Background: Alopecia areata is marked by autoimmune 
assault on the hair follicle resulting in hair loss. T helper 17 
cell subset has important roles in protecting the host against 
extracellular pathogens, however, also promotes inflammatory 
pathology in autoimmune disease, and it expresses both 
interleukin (IL)-17A and IL-17F, which can signal via the 
IL-17 receptor A. Objective: To investigate the significance of 
IL17A and IL17RA gene polymorphisms in the susceptibility 
to alopecia areata. Methods: We conducted case-control 
association study of 238 alopecia areata patients and 270 
matched healthy controls. Allele frequency of total 2 single 
nucleotide polymorphims in the IL17A gene and 4 single 
nucleotide polymorphims in the IL17RA gene were studied. 
The statistical analyses were performed according to onset 
age, the presence of familyhistory, clinical subtypes, and 
presence of nail involvement or body hair involvement. 
Results: One single nucleotide polymorphim (rs879577) of 
IL17RA gene showed significant difference between 
alopecia areata patients group and controls group (p= 
0.0288). One single nucleotide polymorphim (rs4819554) 
of IL17RA gene showed significant difference between the 
early onset and late onset alopecia areata (p=0.0421). 
Conclusion: IL17RA gene polymorphism might contribute to 
the increased susceptibility to alopecia areata in Korean 
population, and IL17RA gene polymorphism may be 
associated with onset age. (Ann Dermatol 24(1) 61∼65, 
2012)
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INTRODUCTION
Alopecia areata (AA) is an organ-specific autoimmune 
disease characterized by T-cell infiltrates and cytokine 
production around anagen-stage hair follicles
1,2. There is 
evidence for loss of immune privilege coupled with T cell 
mediated attack of hair follicle autoantigens
3. The role of T 
helper (Th)1 and Th2 cytokines in the pathogenesis of AA 
have not been fully established. The evidence for the role 
of cytokines and T-cells in AA includes the beneficial 
effects of systemic steroids and calcineurin inhibitors
4,5. 
Autoimmune diseases result from many factors, including 
the interaction of the genetic background of the immune 
system with the environment.   
AA being linked to genetic factors is supported by the fact 
that 4% to 28% of patient’s have a family history
6. It is 
probable that AA and other autoimmune diseases are 
polygenic, with multiple potential routes of genetic 
susceptibility
7. Many studies have been done on the 
linkages of various genes to AA. The most extensive work 
has been established on linkages with the human leuko-
cyte antigen (HLA) hapolotypes and less extensive work 
has also been done on the immune response and other 
genes
6. In addition to HLA genes, there are several known BL Lew, et al
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genetic polymorphisms in cytokine receptors and 
antigen-processing molecules. 
Several studies in the late 1990s implicated interleukin 
(IL)-17 in the pathogenesis of autoimmunity. Elevated 
IL-17 levels were found in rheumatoid arthritis, systemic 
lupus erythematosus, and psoriasis patients, although it 
was not clear from these studies how important a role it 
may play in disease pathogenesis
8,9. The IL-17 cytokine 
family consists of six members: IL-17A, IL-17B, IL-17C, 
IL-17D, IL-17E/IL-25, and IL-17F. The best characterized 
member of this family is IL-17A, and its expression 
facilitates the definition of a newly discovered lineage of 
CD4+ effector T cells, the Th17 subset
10-14. IL-17A is the 
founding member of a novel family of inflammatory 
cytokines that plays a critical role in the pathogenesis of 
many autoimmune diseases, including multiple sclerosis  
and experimental autoimmune encephalomyelitis, but it 
was not clear from these studies how important a role it 
may play in disease pathogenesis
9. The receptor for IL-17, 
which is referred to as IL-17R from here on, is abundantly 
expressed by all cells of the immune system, and 
stimulation of various cell types with IL-17 can induce the 
expression of other cytokines such as IL-1β, TNF and 
IL-6, and the chemokines IL-8 and macrophage inflammatory 
protein 1. In contrast to the restricted set of cells that 
produce IL-17, mRNA of the IL-17R is expressed ubiqui-
tously in many cell types and shares no homology with 
any other cytokine receptor family
15. 
The role of IL-17 on the pathogenesis of AA has not been 
studied yet, but we suggest that IL-17 may be associated 
with AA like other autoimmune diseases. The purpose of 
this study is to determine whether variation in the 




AA patients and control subjects in Kyung Hee University 
Hospital at Gang-dong (Kyung Hee East West Neo 
Medical Center) were enrolled in this study. The control 
subjects were recruited after they had been determined as 
mentally and physically healthy in a general health check- 
up program. AA patients were diagnosed by clinical 
features and physical examination including pull test and 
microscopic analysis of hairs. However, diagnosis of AA 
was confirmed by skin biopsy in some cases. A careful 
history was taken from each patient and concerned 
general health, including the existence of previous AA, 
triggering factors, the presence of autoimmune disease, or 
atopy,  and a family history of AA or autoimmune disease. 
A serologic work-up including an anemia study, venereal 
desease research laboratory test, antinuclear antibodies, a 
thyroid function test, and androgenic hormones, such as 
testosterone, estradiol, luteinizing hormone, and follicle- 
stimulating hormone was carried out for all patients. Two 
hundred and seventy healthy controls (144 males and 126 
females, average age at survey: 35.7) were included. 
Healthy controls did not have any known diseases or 
symptoms. 
 Informed consent was obtained from each subject, and 
the study was approved by the Institutional Review Board 
of Kyung Hee University Hospital at Gang-dong. Genomic 
DNA was prepared from peripheral blood using a 
genomic DNA isolation reagent kit (Core-BioSystem, 
Seoul, Korea). 
Single nucleotide polymorphism (SNP) selection and 
allele frequency 
Two SNPs (rs3819024 [promoter], rs2275913 [promoter]) 
for  IL17A gene and four SNPs (rs4819554 [promoter], 
rs879577 [exon 13, missense Ala367Val], rs2229151 
[exon 13, synonymous  Lys379Lys], and rs875975 [exon 
13 , synonymous  Ile486Ile]) for IL17RA gene with greater 
than 0.3 heterozygosity among SNPs located in the 
promoter or exon (http://www.ncbi.nlm.nih.gov/SNP) were 
selected. All six selected SNPs were included by the 
Hardy-Weinberg Equilibrium test (HWE, p＞0.05). 
The genotypes were determined by direct sequencing. 
Genomic DNA was amplified using the following primers: 
rs3819024 (sense, 5'-GGGTTGGAACATGCCTTTAACA-3'; 
antisense, 5'-AGCTGCTATGCTATGGGTCAAT-3'; 380 
bp); rs2275913 (sense, 5'-TCAAGGTACATGACACCAGAAG-3'; 
antisense, 5'-GATGAGTTTGTGCCTGCTATGA-3'; 394 bp); 
rs4819554 (sense, 5'-CACGCGTGCTAAGAAGGAG-3'; 
antisense, 5'-TATTTTACCCTATACCGGGC-3'; 327 bp); 
rs879577 (sense, 5'-CCTCAGTTGG GTTTCTCAGC-3'; and 
antisense, 5'-TCTAGTAGCAGGACACGAGG-3'); rs2229151 
(sense, 5'-GGTCAGCATGTGTGGTCTTGT-3'; antisense, 
5'-TCAGTACTGGACCCACCCGGC-3'; 327 bp); rs875975 
(sense, 5'-CTCTAAGATCATCGTCCTGTG-3'; antisense, 
5'-CGAGTACCTGTCCAAGCTCCT- 3'; 327 bp). The sam-
ples were sequenced using an ABI Prism 3730XL Analyzer 
(PE Applied Biosystems, Foster City, CA, USA). Sequence 
data were analyzed using the SeqManII Software (DNASTAR 
Inc., Madison, WI, USA). 
Statistical analysis
The HWE for two SNPs was assessed using SNPStats 
(http://bioinfo.iconcologia.net/index.php)
16. A linkage dis-
equilibrium (LD) block of polymorphisms was tested using 
Haploview version 3.32
17. Multiple logistic regression IL17A/IL17RA  Gene Polymorphisms in Alopecia Areata
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Table 1. Demographic and clinical characteristics of AA patients
and the control subjects
Alopecia areata Control
  Number 238 270
  Male/female 109/129 144/126
  Age (yr) 28.6±13.2 35.7±11.8
(9∼51) (11∼48)
  Age of onset
    ＜30 years 162
    ≥30 years  76
  Family Hx
    ( + )  1 9
    ( −) 219
  Type
    Patch 204
    Totalis or universalis  34
  Involvement of nail
    ( + )  3 5
    ( −) 203
  Involvement of body hair
    ( + )  3 5
    ( −) 203
Values are presented as number or mean±standard deviation 
(range). AA: alopecia areata.
Table 2. Logic analysis of IL17A  and  IL17RA  polymorphisms with AA patients and normal control subjects
Gene SNP (rs) Region Allele Case (%) Control (%) 　p-value OR (95% CI)
  IL17A rs2275913 Promoter G 277 58.0 313 57.0 0.5749 0.9317  (0.7265~1.1940)
A 197 42.0 239 43.0 
rs3819024 Promoter A 268 57.0 308 56.0  0.811 0.9703  (0.7576~1.2426)
G 206 43.0 244 44.0
  IL17RA rs879575 Exon13 G 466 98.0 530 96.0  0.0705 0.4727  (0.2062~1.0838)
A 8 2.0 22 4.0 
rs879577 Exon13 G 454 96.0 500 93.0  0.0288 0.5237  (0.2907~0.9436)
A 20 4.0 38 7.0
rs2229151 Exon13 G 315 66.0 361 65.0 0.9617 0.9935  (0.7627~1.2943)
A 158 34.0 191 35.0 
rs4819554 Promoter A 255 55.0 288 53.0  0.5353 0.9228  (0.7158~1.1897)
G 209 45.0 256 47.0 
IL: interleukin, AA: alopecia areata, SNP: single nucleotide polymorphism, OR: odds ratio, CI: confidence internal.
models were calculated for the odds ratio, 95% confi-
dence interval, and corresponding p-values, with controls 
for gender as a covariable. We used SNPStats, Helixtree 
Software (Golden Helix Inc., Boezman, MT, USA), and 
SNPAnalyzer (ISTECH Inc., Goyang, Korea)
18.
RESULTS
In this study, 238 AA patients (109 males and 129 females, 
average age at survey; 28.6 years) were enrolled (Table 1). 
In onset age, one hundred sixty-two patients (68%) were 
under age 30 (early onset) and seventy-six patients (32%) 
were over age 30 (late onset). Nineteen (8%) had a family 
history of AA and 219 (92%) did not have family history. 
Two hundred and four (86%) had patchy type of AA and 
34 patients (14%) had alopecia totalis (AT) or alopecia 
universalis (AU). Thirty-five patients (15%) had concomitant 
nail disorder, but 203 patients (85%) did not. Thirty-five 
patients (15%) had an involvement of body hairs such as 
eyebrow, axillary hairs and pubic hairs, whereas 203 
patients (85%) did not have body hair involvement.
Association between IL17A/IL17RA gene and AA 
patients group
Two SNPs (rs3819024 and rs2275913) in the IL17A gene 
showed no significant difference between the AA patients 
group and the control group (Table 2). Also, the LD block 
in two SNPs of IL17A was not constructed using Gabriel's 
method. One SNP (rs879577) in IL17RA showed a 
significant difference between the AA patient group and 
the control group (Table 2). LD blocks in IL17RA were not 
constructed using Gabriel's method. A block of strong LD 
cannot be observed in the region of IL17RA 4 SNPs, 
which consisted of rs4819554, 879577, 2229151, and 
879575.
Age of onset, family history, clinical subtypes, nail 
involvement and body hair involvement
We investigated differences in the polymorphisms according 
to clinical parameters of AA. 
Age of onset 
One SNP (rs4819554) of IL17RA gene showed significant 
difference between the early onset AA and late onset AA 
(Table 3). However, two SNPs (rs2275913 and rs3819024) 
in  IL17A did not show significant differences between 
early onset and late onset AA (Table 3). 
Presence of family history
There were no significant differences of expression for all BL Lew, et al
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Table 3. Logic analysis of IL17A  and  IL17RA  polymorphisms with early onset or late onset AA patients
Gene SNP (rs) Region Allele Case (%) Control (%) 　p-value OR (95% CI)
  IL17A rs2275913 Promoter G 85 57.0 192 60.0  0.7645 1.0620  (0.7165~1.5740)
A 65 43.0 130 40.0 
rs3819024 Promoter A 81 56.0 187 58.0  0.6426 0.9112  (0.6151~1.3498)
G 69 44.0  　 135 42.0
  IL17RA rs879575 Exon13 G 146 98.0 318 99.0  0.7016 0.7306  (0.1457~3.6632)
A 4 2.0 4 1.0 
rs879577 Exon13 G 145 95.0 307 96.0  0.0641 2.2899  (0.9319~5.6268)
A 7 5.0 13 4.0
rs2229151 Exon13 G 95 63.0 219 68.0  0.3294 0.8125  (0.5351~1.2337)
A 55 37.0 103 32.0 
rs4819554 Promoter A 81 55.0 174 55.0  0.0421 1.5074  (1.0137~2.2415)
G 67 45.0 140 45.0 
IL: interleukin, AA: alopecia areata, SNP: single nucleotide polymorphism, OR: odds ratio, CI: confidence internal.
Table 4. Genotype frequencies of rs879577 in each population
Genotype
Korean
European Chinese Japanese Sub-Saharan
Alopecia areata Control
GG 0.92 0.86 0.383 0.822 0.800 0.183
GA 0.08 0.14 0.483 0.178 0.200 0.517
AA 0.00 0.00 0.133 0.000 0.000 0.300
This data is from the SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP). SNP: single nucleotide polymorphism.
SNPs of IL17A and IL17RA gene between the AA patients 
with family history of AA and those without (data not 
shown). 
Clinical subtype
There were no significant differences of expression for all 
the SNPs in IL17A and IL17RA between patchy type of AA 
and AU or AT (data not shown). 
Nail involvement and body hair involvement
There were no significant differences of expression for all 
the SNPs in IL17A and IL17RA between presence of nail 
involvement and normal nail appearance (data not shown). 
Also, there were no significant differences in the expre-
ssion of all SNPs between the presence and absence of 
body hair involvement (data not shown).
DISCUSSION
In AA, the origin of the disease process is not fully 
understood. However, there are indications for a T-cell- 
mediated autoimmune process directed against an unknown 
autoantigen of the hair follicle. T lymphocytes that have 
been shown to be oligoclonal and autoreactive are pre-
dominantly present in the peribulbous inflammatory 
infiltrate
19. It has been hypothesized that AA is an organ- 
specific autoimmune disease with genetic predisposition 
and an environmental trigger
20,21. 
Several studies of SNPs in AA have been reported. Tazi- 
Ahnini et al.
22 found significant association between the 
rare allele (C961) of the AIRE polymorphism at position 
961 and AA. This association is stronger and more significant 
with the severe form of the condition (AU). They also 
examined two polymorphisms in the coding sequence of 
the Notch4 gene at positions +1297 and +3063 in a 
case-control study of 116 AA patients and 142 healthy 
control subjects. The initial analysis showed a significant 
association of AA in the overall data set with the Notch4 
(T1297C) polymorphism but not with Notch4 (A+3063G)
23. 
They analyzed polymorphisms of IL-1ra (IL1RN+2018) 
and its homologue IL-1L1 (IL1L1+4734) in a case-control 
association study on 165 patients and a large number of 
matched controls. The polymorphisms within IL1RN and 
IL1L1 themselves or a gene in linkage disequilibrium with 
IL1RN and IL1L1 predispose to the more severe forms of 
AA
24. The polymorphisms within the MIF-173*C allele 
confer an increased risk of susceptibility to extensive 
forms of AA, especially with an early onset of disease. MIF 
is therefore suggested to be closely implicated in the 
pathogenesis of more extensive forms of AA
25. The present 
study is, to the best of our knowledge, the first study to 
investigate a potential influence of IL17A and IL17RA IL17A/IL17RA  Gene Polymorphisms in Alopecia Areata
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gene polymorphisms in AA patients. 
The action and expression of IL-17RA on the hair follicle 
has not been evaluated yet. Therefore, expression of 
IL-17RA in the hair follicles and its role in pathophysiology 
of AA should be investigated in the future. The rs879577 
SNP which was shown to have significantly different 
expression in AA patients compared to healthy controls is 
located in the missense exonal region of the IL17RA gene 
located on chromosome 22. In this SNP, the AA, AG and 
GG genotype frequencies are reported respectively to be 
0.133, 0.483, and 0.383 in European, 0.000, 0.178, and 
0.822 in Chinese, 0.000, 0.200, 0.800 in the Japanese 
population (http://www.ncbi.nlm.nih.gov/SNP; Table 4). 
We have demonstrated for the first time that IL17RA 
polymorphisms have the possibilities of determining the 
pathophysiology of AA or expression of AA phenotypes. 
In this study, the expression of rs4819554 polymorphism 
of IL17RA gene can influence the onset time of AA. 
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